Authors : Ramya G. K.; Pradesh C.; Jeevitha M.; Arul Prakasam K. C.

Volume/Issue : Volume 10 - 2025, Issue 9 - September

Google Scholar : https://tinyurl.com/z95xdypw

Scribd : https://tinyurl.com/45e3fv4b

DOI : https://doi.org/10.38124/ijisrt/25sep861

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Nephrotic syndrome (NS) is a clinical entity characterized by massive proteinuria (>3.5 g/day), hypoalbuminemia, edema, and hyperlipidemia, reflecting glomerular filtration barrier injury rather than a single disease. The condition is classified as either primary, due to intrinsic glomerular disease such as focal segmental glomerulosclerosis (FSGS), membranous nephropathy, and minimal change disease, or secondary, resulting from systemic disorders such as diabetes mellitus. Idiopathic nephrotic syndrome is increasingly understood as an immune-mediated process, with both T-cell and B- cell dysregulation contributing to podocyte injury and proteinuria. Complications include infection, thromboembolic events, and progressive renal dysfunction, with incidence rates varying between children (1.15–16.9/100,000) and adults (≈3/100,000 annually). Diagnosis is established through protein quantification (spot urine protein/creatinine ratio or 24-hour urine collection) and supported by biochemical findings including hypoalbuminemia and hyperlipidemia. Management is multifaceted, targeting reduction of proteinuria, control of edema, prevention of complications, and achievement of remission. Treatment strategies include sodium and fluid restriction, diuretics, immunosuppressive therapy, and renin– angiotensin system inhibitors. Evidence supporting routine use of ACE inhibitors or ARBs for improved clinical outcomes remains mixed, though their antiproteinuric effect is well recognized. Supportive care, including infection prevention, anticoagulation in high-risk patients, and management of dyslipidemia, is critical. Despite its rarity, NS poses significant morbidity and risk for progression to chronic kidney disease or end-stage kidney disease, highlighting the need for early diagnosis, individualized therapy, and long-term follow-up to optimize patient outcomes.

Keywords : Nephrotic Syndrome, Proteinuria, Podocyte Injury, Edema, Diuretics, Immunosuppression, Renin–Angiotensin System Blockers.

References :

1. Wendt R, Sobhani A, Diefenhardt P, Trappe M, Völker L A. An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes. Biomedicines. 2024;12(10):2259. doi: 10.3390/biomedicines12102259.
2. Tecile Prince Andolino, MD, Jessica Reid-Adam, MD . Nephrotic Syndrome .Vol.36 No.3  MARCH 2015.
3. Zhu S, Zhang J, Gao L, Ye Q, Mao J. The Pathogenesis of Nephrotic Syndrome: A Perspective from B Cells. Kidney Diseases. 2024;10:531–544. doi: 10.1159/000540511.
4. Lin R, McDonald G, Jolly T, Batten A, Chacko B. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney International Reports. 2020;5:435–447. doi: 10.1016/j.ekir.2019.12.001.
5. Frontières Editorial Team—Ethnic Differences in Childhood Nephrotic Syndrome. Frontiers in Pediatrics. 2016;4:39. doi: 10.3389/fped.2016.00039.
6. Gates B. Colbert MD b,Nida Hamiduzzaman MD a. Nephrotic Syndrome. Primary Care: Clinics in Office Practice Volume 47, Issue 4, December 2020, Pages 597-613. https://doi.org/10.1016/j.pop.2020.08.002
7. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008;336(7654):1185-1189.
8. Nishi S, Ubara Y,Matsuo S. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016 Jun;20(3):342-70. doi: 10.1007/s10157-015-1216-x. PMID: 27099136; PMCID: PMC4891386.
9. Kitiyakara C, Kopp JB, Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23(2):172-182.
10. Charles kodner MD,Am Fam Physician. Nephrotic Syndrome in Adults: Diagnosis and Management. 2009;80(10):1129-1134.
11. Leung YY, Szeto CC, Tam LS, et al. Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Rheuma-tology (Oxford). 2007;46(4):649-652.
12. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis. 1993;22(1):135-142.
13. Charles kodner MD,Am Fam Physician. Nephrotic Syndrome in Adults: Diagnosis and Management.2016;93(6):479-48
14. Politano SA, Colbert GB, Hamiduzzaman N: Nephrotic syndrome. Prim Care. 2020, 47:597-613. 10.1016/j.pop.2020.08.002 2.
15. Walz G: Pathogenetic aspects of nephrotic syndrome [Article in German] . Internist (Berl). 2003, 44:1075-82. 10.1007/s00108-003-1031-4
16. Priyanshu R. Verma , Praful Patil. Nephrotic Syndrome: A Review. DOI: 10.7759/cureus.53923.
17. PanelDil Sahali a b, Vincent Audard a b , Philippe Remy a b , Philippe Lang a b.,Idiopathic nephrotic syndromes: pathophysiology and specific therapeutic management in adults Pathogenesis and treatment of idiopathic nephrotic syndrome in adults. Volume 8, Issue 3 ,June 2012, Pages 180-192 https://doi.org/10.1016/j.nephro.2011.11.010.
18. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008;336(7654):1185-1189.
19. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387-395.
20. Arneil GC. Management of the nephrotic syndrome. Arch Dis Child. 1968 Apr;43(228):257-62. doi: 10.1136/adc.43.228.257. PMID: 4868924; PMCID: PMC2019850.
21. Floege J. Introduction to glomerular disease: clinical presentations. In: Johnson RJ, Feehally J, Floege J, eds. Comprehensive Clinical Nephrology. 5th ed. Philadelphia, Pa.: Elsevier Saunders; 2015.
22. Furosemide dosage. Drugs.com. http://www.drugs.com/dosage/furosemide.html. Accessed January 13, 2016.
23. Wu HM, Tang JL, Cao L, Sha ZH, Li Y. Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst Rev. 2012;4:CD003964.
24. Mahmoodi BK, Mulder AB, Waanders F, et al. The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria. J Thromb Haemost. 2011;9(12):2416-2423.
25. Chen Y, Schieppati A, Chen X, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2014;10:CD004293.